Anti-CD20 therapy for the treatment of chronic graft versus host disease.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 May 2009 Additional lead trial centres reported by Netherlands Trial Register.
- 02 May 2009 Planned end date changed from 1 Jul 2008 to 1 Nov 2010 as reported by Netherlands Trial Register.
- 02 May 2009 New source identified and integrated (Netherlands Trial Register NTR1222).